Napredna pretraga

Pregled bibliografske jedinice broj: 926453

GLYCOPHENOTYPE OF BREAST AND PROSTATE CANCER STEM CELLS TREATED WITH THIENO [2, 3-b] PYRIDINE ANTICANCER COMPOUND


Angela Mastelić, Anita Markotić, Vedrana Čikeš Čulić, Nikolina Režić Mužinić, Milena Vuica- Ross, David Barker, Duje Apostolski, Jóhannes Reynisson
GLYCOPHENOTYPE OF BREAST AND PROSTATE CANCER STEM CELLS TREATED WITH THIENO [2, 3-b] PYRIDINE ANTICANCER COMPOUND // 40th Anniversary HDBMB2016
Split, Hrvatska, 2016. str. 91-91 (poster, domaća recenzija, sažetak, znanstveni)


Naslov
GLYCOPHENOTYPE OF BREAST AND PROSTATE CANCER STEM CELLS TREATED WITH THIENO [2, 3-b] PYRIDINE ANTICANCER COMPOUND

Autori
Angela Mastelić, Anita Markotić, Vedrana Čikeš Čulić, Nikolina Režić Mužinić, Milena Vuica- Ross, David Barker, Duje Apostolski, Jóhannes Reynisson

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
40th Anniversary HDBMB2016 / - , 2016, 91-91

Skup
Congress of the Croatian Society of Biochemistry and Molecular Biology on the Occasion of the 40th Anniversary

Mjesto i datum
Split, Hrvatska, 1.-4. 6. 2016

Vrsta sudjelovanja
Poster

Vrsta recenzije
Domaća recenzija

Ključne riječi
Breast, prostate, cancer stem cells, GM3, CD15s

Sažetak
The emerging paradigm posits that tumor progression is driven by a small subpopulation of cancer stem cells (CSC characterized by CD44+/CD24- phenotype). We investigated the influence of a newly developed thienopyridine anticancer compound (3-amino-5-oxo-N-phenyl-5, 6, 7, 8- tetrahydrothieno[2, 3-b]quinoline-2-carboxamide, 1) on the growth, survival and glycophenotype (CD15s and GM3) of breast and prostate cancer stem/progenitor-like cell population. Breast triple-negative MDA-MB-231 and prostate Du-145 cancer cells were incubated with compound 1 alone, or in combination with paclitaxel. The cellular metabolic activity was determined by the MTT assay. The type of cell death induced by 48h treatment was assessed using combination of Annexin-V-FITC and propidium iodide staining. Additional flow cytometric analysis was performed to detect percentage of CD44+/CD24- cells, and GM3 and CD15s positive CSC, as well as the expression of GM3 and CD15s per one CSC, in both cell lines. Compound 1 produces a dose- and time-dependent cytotoxicity, mediated mainly by apoptosis in breast cancer cells, and slightly (2.3%) but statistically significant lowering breast CSC subpopulation. GM3 expression per one breast CSC was increased and the percentage of prostate GM3+ CSC subpopulation was decreased in cells treated with 1 compared to non-treated cells. The percentage of CD15s+ CSC was lower in both cell lines after treatment with compound 1. Considering that triple-negative breast cancers are characterized by an increased percentage of breast cancer stem cells and knowing their association with an increased risk of metastasis and mortality, 1 is a potentially effective drug for triple-negative breast cancer treatment.

Izvorni jezik
Engleski



POVEZANOST RADA